Cargando…

Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): a case report

BACKGROUND: Mucopolysaccharidosis VI, or Maroteaux–Lamy disease, is an autosomal recessive disease characterized by deficiency of the enzyme arylsulfatase B in the lysosomal catabolism of glycosaminoglycans. Due to reduced (or even null) enzyme activity, glycosaminoglycans (mainly dermatan sulfate)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrade, Isadora, Ribeiro, River, Carneiro, Zumira A., Giugliani, Roberto, Pereira, Catarina, Cozma, Claudia, Grinberg, Daniel, Vilageliu, Lluïsa, Lourenco, Charles M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787900/ https://www.ncbi.nlm.nih.gov/pubmed/35078524 http://dx.doi.org/10.1186/s13256-021-03240-3

Ejemplares similares

Hemifacial Spasm in Mucopolysaccharidosis Type VI (Maroteaux–Lamy Syndrome)
por: Karir, Aneesh, et al.
Publicado: (2018)

Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) in the pre-Columbian culture of Colombia
por: Pachajoa, Harry, et al.
Publicado: (2014)

Molecular findings of Colombian patients with type VI mucopolysaccharidosis (Maroteaux–Lamy syndrome)
por: Giraldo, Gustavo Adolfo, et al.
Publicado: (2015)

Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI)
por: Saccone, Paola, et al.
Publicado: (2014)

Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients
por: Leiro, Beth, et al.
Publicado: (2021)

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
por: El Dib, Regina P, et al.
Publicado: (2009)

Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux–Lamy syndrome): under-recognized and challenging to diagnose
por: Lachman, Ralph S., et al.
Publicado: (2014)

Fundoscopic Changes in Maroteaux-Lamy Syndrome
por: Magalhães, Augusto, et al.
Publicado: (2019)

Home treatment of type VI mucopolysaccharidosis (Maroteaux‐Lamy syndrome) an alternative at this time of COVID‐19 pandemic: A case in Peru
por: Cortez Miranda, Jenny Lucy, et al.
Publicado: (2020)

Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux–Lamy syndrome)
por: Lin, Hsu-Ying, et al.
Publicado: (2019)

Airway hitches and management in Maroteaux-Lamy syndrome
por: Kamat, Uma, et al.
Publicado: (2022)

Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
por: Dilger, Hansjörg, et al.
Publicado: (2013)

Anesthesia in a child with Maroteaux-Lamy syndrome undergoing mitral valve replacement
por: Sayilgan, Cem, et al.
Publicado: (2012)

Atlantoaxial instability in a case of Maroteaux–Lamy syndrome
por: Shah, Abhidha, et al.
Publicado: (2021)

Double valve replacement in a patient with Maroteaux – Lamy syndrome as an ultimate team challenge
por: Demis, Alexandros Agron, et al.
Publicado: (2021)

Multiple Dentigerous Cysts as a Rare Presentation of Maroteaux–Lamy Syndrome
por: Shah, Ajaz Ahmad, et al.
Publicado: (2017)

Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome
por: Ebbink, Berendine J., et al.
Publicado: (2015)

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase
por: Brands, Marion M, et al.
Publicado: (2013)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Lamy fiscal
por: Bonafoux, Philippe
Publicado: (1990)

Lamy fiscal
por: Bonafoux, Philippe
Publicado: (1990)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Visual impairment in mucopolysaccharidosis VI
por: Magalhães, Augusto Monteiro, et al.
Publicado: (2023)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children()
por: Horovitz, Dafne D.G., et al.
Publicado: (2015)

SR proteins and the nonsense-mediated decay mechanism are involved in human GLB1 gene alternative splicing
por: Santamaria, Raül, et al.
Publicado: (2008)

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013)

Vertebral Tongue-Like Deformity in Mucopolysaccharidosis VI
por: Landen, Michiel, et al.
Publicado: (2021)

Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia
por: Voskoboeva, Elena, et al.
Publicado: (2022)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Mucopolysaccharidosis Type VI with Recurrent Chest Infection
por: Numan, Ashraf, et al.
Publicado: (2023)

Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches
por: Benetó, Noelia, et al.
Publicado: (2020)

Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI
por: Eliyahu, Efrat, et al.
Publicado: (2011)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
por: Harmatz, Paul, et al.
Publicado: (2010)

Mucopolysaccharidosis VI in cats – clarification regarding genetic testing
por: Lyons, Leslie A., et al.
Publicado: (2016)

Visual Dysfunction of Type I and VI Mucopolysaccharidosis Patients Evaluated with Visual Evoked Cortical Potential
por: Gomes, Bruno Duarte, et al.
Publicado: (2012)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4j0t0hulgjdtl1uplq0d62uhmg